Finding the best ways to prevent cancer in kidney transplant patients from Epstein-Barr Virus.
Determining Optimal Immunosuppression and Kidney Allocation Strategies for Mitigating Risks from Epstein-Barr Virus in Kidney Transplant Centers
This study is looking at how different ways of lowering the immune system's activity can help kidney transplant patients who receive organs from donors with a virus called Epstein-Barr, and it hopes to find better ways to prevent complications after the transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11107209 on NIH RePORTER |
What this research studies
This research investigates how different immunosuppression strategies affect kidney transplant patients who receive organs from donors with Epstein-Barr Virus (EBV). It aims to understand the relationship between immunosuppression and the risk of developing post-transplant lymphoproliferative disorder (PTLD) due to EBV infection. The study will also explore how prioritizing kidney allocation from EBV-seronegative donors to EBV-seronegative recipients can help reduce complications. By collaborating with multiple kidney transplant centers, the research seeks to gather comprehensive data to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are kidney transplant recipients who are EBV-seronegative and have received organs from EBV-seropositive donors.
Not a fit: Patients who are EBV-seropositive or those who do not require kidney transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower the risk of cancer in kidney transplant patients by optimizing immunosuppression and kidney allocation strategies.
How similar studies have performed: Previous research has shown promising results in optimizing immunosuppression strategies to reduce cancer risks in transplant patients, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Potluri, Vishnu Sagar — University of Pennsylvania
- Study coordinator: Potluri, Vishnu Sagar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.